Oncolytics Biotech (ONCY) Total Non-Current Liabilities (2009 - 2022)

Oncolytics Biotech (ONCY) has 11 years of Total Non-Current Liabilities data on file, last reported at $8.0 million in Q4 2022.

• On a quarterly basis, Total Non-Current Liabilities rose 63.21% year-over-year to $8.0 million in Q4 2022; TTM through Dec 2022 was $8.0 million, a 63.21% increase from a year earlier, with the FY2022 full-year figure at $8.3 million, up 69.42% from the prior year.
• Total Non-Current Liabilities for Q4 2022 stood at $8.0 million, up from $4.6 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for ONCY reached as high as $8.8 million in Q3 2019 and fell as low as $4.4 million in Q4 2018.
• Historically, Total Non-Current Liabilities has averaged $6.1 million across 5 years, with a median of $5.8 million in 2018.
• On a YoY basis, Total Non-Current Liabilities climbed as much as 100.0% in 2018 and fell as far as 100.0% in 2018.
• Year by year, Total Non-Current Liabilities stood at $4.4 million in 2018, then rose by 17.77% to $5.2 million in 2019, then gained by 1.07% to $5.3 million in 2020, then decreased by 7.4% to $4.9 million in 2021, then surged by 63.21% to $8.0 million in 2022.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $8.0 million in Q4 2022, $4.6 million in Q1 2022, and $4.9 million in Q4 2021.